A research and development-driven manufacturer of specialty chemicals, Ami Organics Limited, will launch its initial public offer (IPO) on Sep 01, 2021. The offer will close on Sep 03, 2021 and the company has fixed the price band at ₹603-610 per equity share.
About Ami Organics Limited
Ami Organic Limited is a research and development-driven manufacturer of specialty chemicals with varied end usage, focussed towards the development and manufacturing of pharma intermediates for regulated and generic active pharmaceutical ingredients (“APIs”) & New Chemical Entities (“NCE”) and key starting material for agrochemical and fine chemicals. The company is the major manufacturers of Pharma Intermediates for certain key APIs, including Dolutegravir, Trazodone, Entacapone, Nintedanib and Rivaroxaban.
Ami Organics Limited IPO Issue Details
|OPENS ON:||Sep 1, 2021|
|CLOSES ON:||Sep 3, 2021|
|Price band:||₹603 to ₹610 per equity share|
|Lot size:||24 Shares|
|One lot costing:||₹14,640|
|Face Value:||₹10 per equity share|
|Listing on:||NSE, BSE|
|Issue size:||₹569.64 crores (Fresh issue: ₹200.00 crores + Offer For Sale: ₹369.64 crores)|
|Shareholding:||Promoter holding will stand at 41.05% post-issue from 47.23% pre-issue.|
Will list on the exchange on Sep 14, 2021.
Objects of the issue:
➢ Repayment/prepayment of certain financial facilities availed by the company.
➢ Funding working capital requirements of the company.
➢ General corporate purposes.
Interesting facts about Ami Organics Limited IPO:
- Ami Organics Limited supplies products to more than 150 customers directly in India and in 25 countries overseas. Some of its domestic customers include Laurus Labs Limited, Cadila Healthcare Limited and Cipla Limited and some of its key export customers include Organike s.r.l.a Socio Unico, Fermion Oy, Fabbrica Italiana Sintetici S.p.A, Chori Co. Ltd., Medichem S.A. and Midas Pharma GmbH.
- The company has three manufacturing facilities in Gujarat situated at Sachin, Ankleshwar & Jhagadia, with an aggregate installed capacity of 6,060 MTPA.
- It has developed and commercialised over 450 Pharma Intermediates for APIs across 17 key therapeutic areas and NCE. The Pharma Intermediates which it manufactures find application in certain high-growth therapeutic areas including anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant and anti-coagulant.
- Considering the FY-21 adjusted EPS of Rs.14.82 on a post-issue basis, the company is going to list at a P/E of 41.16 with a market cap of Rs.22,227 mn while its peers namely Aarti Industries and Hikal are trading at a P/E of 54.20 and 46.13 respectively.